Katharina Glatz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katharina Glatz has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Alfred Zippelius
Laboratory of Cancer Immunology, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland
17 shared publications - Andreas Buser
Regional Blood Transfusion Service, Swiss Red Cross
17 shared publications - Andreas Holbro
Division of Hematology, University Hospital Basel, Basel, Switzerland
17 shared publications - Andreas Zingg
Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
17 shared publications - Benjamin Kasenda
Division of Medical Oncology, University Hospital Basel, Basel, Switzerland
17 shared publications - Christoph Kettelhack
Visceral Surgery, Clarunis University Center for Gastrointestinal and Liver Disease, University Hospital and Claraspital Basel, Basel, Switzerland. 6
17 shared publications
Latest Publications
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 3. Regressing soft tissue metastasis (Biopsy 10 weeks after TIL transfer). No vital tumor is detectable.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 3. Regressing soft tissue metastasis (Biopsy 10 weeks after TIL transfer). No vital tumor is detectable.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 6. Expression analysis of selected exhaustion markers on different T cells on T cells in the tumor lesion used for TIL expansion.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 6. Expression analysis of selected exhaustion markers on different T cells on T cells in the tumor lesion used for TIL expansion.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 7. MHC I expression on tumor cells in lesion used for expansion of the TIL product and the progressing lung metastasis.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 7. MHC I expression on tumor cells in lesion used for expansion of the TIL product and the progressing lung metastasis.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 5. Reactivity assay of TIL product to the primary tumor. CD3+ T cells from the TIL product were tested for intracellular cytokine upregulation against a tumor cell line (TCL) derived from the resected lesion. Anti-CD3/CD28 stimulation was used as positive control. As a negative control, we used HLA blockade.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 5. Reactivity assay of TIL product to the primary tumor. CD3+ T cells from the TIL product were tested for intracellular cytokine upregulation against a tumor cell line (TCL) derived from the resected lesion. Anti-CD3/CD28 stimulation was used as positive control. As a negative control, we used HLA blockade.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 7. MHC I expression on tumor cells in lesion used for expansion of the TIL product and the progressing lung metastasis.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 7. MHC I expression on tumor cells in lesion used for expansion of the TIL product and the progressing lung metastasis.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 2. Regressing soft tissue metastasis (Biopsy 3 weeks after TIL transfer). Vital tumor areas (SOX10) are densely infiltrated by CD8 positive tumor infiltrating lymphocytes as shown by immunohistochemistry.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 2. Regressing soft tissue metastasis (Biopsy 3 weeks after TIL transfer). Vital tumor areas (SOX10) are densely infiltrated by CD8 positive tumor infiltrating lymphocytes as shown by immunohistochemistry.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 4. Progressing lung metastasis (Wedge resection 61 weeks after TIL transfer). The resected lung metastasis is Melan-A positive without any desmoplastic component.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 4. Progressing lung metastasis (Wedge resection 61 weeks after TIL transfer). The resected lung metastasis is Melan-A positive without any desmoplastic component.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 5. Reactivity assay of TIL product to the primary tumor. CD3+ T cells from the TIL product were tested for intracellular cytokine upregulation against a tumor cell line (TCL) derived from the resected lesion. Anti-CD3/CD28 stimulation was used as positive control. As a negative control, we used HLA blockade.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 5. Reactivity assay of TIL product to the primary tumor. CD3+ T cells from the TIL product were tested for intracellular cytokine upregulation against a tumor cell line (TCL) derived from the resected lesion. Anti-CD3/CD28 stimulation was used as positive control. As a negative control, we used HLA blockade.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 1. Study Design of the BaseTIL trial. The BaseTIL trial was a phase I trial of tumor-infiltrating lymphocyte (TIL) therapy in combination with low dose interleukin-2 (IL2) and PD1 blockade with nivolumab for patients with metastatic melanoma.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 1. Study Design of the BaseTIL trial. The BaseTIL trial was a phase I trial of tumor-infiltrating lymphocyte (TIL) therapy in combination with low dose interleukin-2 (IL2) and PD1 blockade with nivolumab for patients with metastatic melanoma.